Director Gillian Cannon exits Corcept (CORT) board but stays on as consultant

Rhea-AI Filing Summary

Corcept Therapeutics Incorporated reported that board member Gillian Cannon, Ph.D. has resigned from its Board of Directors, effective October 10, 2025. The company states that Dr. Cannon did not resign because of any disagreement regarding its operations, financial statements, policies or practices, indicating this is a non-controversial transition.

Corcept has entered into a Consulting Services Agreement with Dr. Cannon, effective as of her resignation date, under which she will provide consulting services to the Board until the company’s 2026 stockholder meeting. As compensation, she will receive a cash fee of $5,708.33 per month, and her previously granted, outstanding stock options will continue to vest on their original schedules during the consulting term.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

FAQ

Why did Gillian Cannon resign from Corcept Therapeutics (CORT)'s board?

Corcept states that Gillian Cannon, Ph.D. resigned from its Board of Directors effective October 10, 2025, and that her resignation was not due to any disagreement with the company on operations, financial statements, policies or practices.

Will Gillian Cannon continue working with Corcept Therapeutics (CORT) after her board resignation?

Yes. Corcept and Dr. Cannon entered into a Consulting Services Agreement under which she will provide consulting services to the Board from the effective date of her resignation until the company’s 2026 stockholder meeting.

How much will Corcept Therapeutics (CORT) pay Gillian Cannon under the consulting agreement?

Under the Consulting Services Agreement, Dr. Cannon will receive a cash fee of $5,708.33 per month for her consulting services to the Board.

What happens to Gillian Cannon’s stock options at Corcept Therapeutics (CORT)?

The agreement provides that during her consulting term, Dr. Cannon’s previously awarded and currently outstanding stock options will continue to vest according to their original vesting schedules.

When does the consulting term for Gillian Cannon end at Corcept Therapeutics (CORT)?

Dr. Cannon’s consulting term runs from the October 10, 2025 effective date of her resignation until the 2026 meeting of stockholders of Corcept Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/06/2025 - 04:36 PM Learn about SEC filing dates

CORCEPT THERAPEUTICS INC false 0001088856 0001088856 2025-10-06 2025-10-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 6, 2025

Corcept Therapeutics Incorporated

(Exact Name of Registrant as Specified in its Charter)

Delaware		000-50679		77-0487658
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

101 Redwood Shores Parkway

Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 327-3270

Registrant’s telephone number, including area code

Not Applicable

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CORT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 6, 2025, Gillian Cannon, Ph.D., notified the Board of Directors (the “Board”) of Corcept Therapeutics Incorporated (the “Company”) of her resignation from the Board, effective as of October 10, 2025 (the “Effective Date”). Dr. Cannon did not resign because of any disagreement with the Company on any matter relating to the Company’s operations, financial statements, policies or practices.

The Board thanks Dr. Cannon for her years of service and valuable contributions to the Company.

Consulting Services Agreement

In connection with Dr. Cannon’s resignation, the Company and Dr. Cannon entered into a Consulting Services Agreement (the “Agreement”), effective as of the Effective Date, pursuant to which Dr. Cannon will provide consulting services to the Board from the Effective Date until the 2026 meeting of stockholders of the Company. Pursuant to the Agreement, Dr. Cannon will be paid a cash fee of $5,708.33 per month. The Agreement further provides that during Dr. Cannon’s consulting term with the Company, Dr. Cannon’s previously awarded and currently outstanding stock options shall continue to vest according to the original vesting schedule of each such stock option.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 6, 2025				CORCEPT THERAPEUTICS INCORPORATED
				By:		/s/ Atabak Mokari
				Name:		Atabak Mokari
				Title:		Chief Financial Officer